Showing results (21-30 of 82) with videos related to

Sort By:
Pageof 9
Pulmonary Therapy|February 7, 2020
Treatment Patterns of New Users of Fluticasone Furoate/Vilanterol in Asthma and COPD in UK Primary Care: Retrospective Cohort StudyDaniel Dedman, Sonia J Coton, Rebecca E Ghosh, et al.
The European Respiratory Journal|October 12, 2013
A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPDAlvar Agustí, Luis de Teresa, Wilfried De Backer, et al.
Respiratory Medicine|January 22, 2013
Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trialFernando J Martinez, Joseph Boscia, Gregory Feldman, et al.
Chest|January 14, 2012
The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trialNicola A Hanania, Gregory Feldman, Wolfgang Zachgo, et al.
Therapeutic Advances in Respiratory Disease|October 21, 2020
Effect of once-daily fluticasone furoate/vilanterol <i>versus</i> vilanterol alone on bone mineral density in patients with COPD: a randomized, controlled trialFrancois Maltais, Isabelle Schenkenberger, Pascal L M L Wielders, et al.
BMJ Open|October 25, 2013
Shortness of Breath with Daily Activities questionnaire: validation and responder thresholds in patients with chronic obstructive pulmonary diseaseMichael L Watkins, Teresa K Wilcox, Maggie Tabberer, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|January 6, 2006
Fluticasone propionate HFA-134a pressurized metered-dose inhaler in adolescents and adults with moderate to severe asthmaJacob L Pinnas, Michael J Noonan, Steven F Weinstein, et al.
The Journal of Pediatrics|August 30, 2005
Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthmaNancy K Ostrom, Bruce A Decotiis, William R Lincourt, et al.
International Journal of Chronic Obstructive Pulmonary Disease|July 1, 2021
Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical TrialsNicola A Hanania, Scott Caveney, Tedi Soule, et al.
Respiratory Medicine|July 8, 2014
Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patientsMark T Dransfield, Gregory Feldman, Phillip Korenblat, et al.
Pageof 9